July 3-5 2014, EACPT organizes the 2014 EACPT focus meeting 'Drugs to Fight Cardiovascular Damage'.
Location: Radboud university medical center, Nijmegen, the Netherlands.
Targeted audience: clinical pharmacologists, pharmacologists, (junior) scientists and clinicians interested in drug treatment of cardiovascular disease.
Topics include: ultrasound imaging of vascular injury (including workshop to get hands-on training), microbioma and inflammation in metabolic syndrome, targeting inflammation to prevent and treat atherosclerosis, diagnosis and therapy of adrenal hypertension, protection against ischemic-reperfusion injury.
Apart from state of the art lectures by invited speakers, academic and industrial scientists are cordially invited to submit their latest scientific results for oral or poster presentation.
For more information: rvanhugten@kenes.
Attached is the article on the policy context for EACPT, which appeared in the Autumn 2013 seventh edition of the policy community publication Science & Technology.
Proactive Pharmacovigilance, Risk Management and Pharmacovigilance in the Era of Personalised Medicine
Recent changes in the pharmacovigilance legislation in various regions in the world have introduced mandatory elements to pharmacovigilance practice, some of which are new, others have been developed further. In this advanced course, two important elements will be elucidated, with a focus on proactive risk management, quality assessment and the role of rapidly evolving pharmacogenomics in pharmacovigilance. The training course will be offering opportunity for open discussions and thoughts on how to fill empty spaces in good pharmacovigilance practice.
On behalf of the local organizing committee it is our great pleasure to invite you to participate in the 20th International Symposium on Microsomes and Drug Oxidations, to be held May 18th to 22nd, in Stuttgart, capital of the Southwestern state of Germany, Baden-Württemberg. Learn more about the event here.
The EMA has launched a campaign advising on the black triangle appearing in the patient leaflet of some medicinal products. For further informations please visit the link:
There is a presentation about the summary of activities of the Innovative Medicines Initiative (IMI1) and the future plans for IMI2.